Why have this procedure in China specifically?

China offers high-quality anti-VEGF biosimilars at a fraction of the cost in Western countries—the entire three-dose loading regimen averages around $1,800, compared to $5,000–$10,000 abroad. Chinese ophthalmology centers use the same advanced injection protocols and equipment as international standards, and many surgeons perform hundreds of these procedures annually, ensuring technical proficiency. Combined with streamlined outpatient care, this makes China a cost-effective and reliable option for patients seeking affordable, evidence-based treatment.